Journal
DISEASE MODELS & MECHANISMS
Volume 12, Issue 9, Pages -Publisher
COMPANY BIOLOGISTS LTD
DOI: 10.1242/dmm.040386
Keywords
Central nervous system; In vitro; CRISPR/Cas9; Mouse; Human; Xenograft; GBM; Cancer; Brain tumour
Categories
Funding
- Cancer Research UK Senior Research Fellowship [A19778]
- Brain Tumour Charity Quest for Cures Collaborative Team Award [GN-000358]
- Cancer Research UK Centre Accelerator Grant [A21992]
- Edinburgh Cancer Research UK Centre, Clinical Research Fellowship
Ask authors/readers for more resources
Glioblastoma multiforme (GBM) is one of the deadliest human cancers. Despite increasing knowledge of the genetic and epigenetic changes that underlie tumour initiation and growth, the prognosis for GBM patients remains dismal. Genome analysis has failed to lead to success in the clinic. Fresh approaches are needed that can stimulate new discoveries across all levels: cell-intrinsic mechanisms (transcriptional/epigenetic and metabolic), cell-cell signalling, niche and microenvironment, systemic signals, immune regulation, and tissue-level physical forces. GBMs are inherently extremely challenging: tumour detection occurs too late, and cells infiltrate widely, hiding in quiescent states behind the blood-brain barrier. The complexity of the brain tissue also provides varied and complex microenvironments that direct cancer cell fates. Phenotypic heterogeneity is therefore superimposed onto pervasive genetic heterogeneity. Despite this bleak outlook, there are reasons for optimism. A myriad of complementary, and increasingly sophisticated, experimental approaches can now be used across the research pipeline, from simple reductionist models devised to delineate molecular and cellular mechanisms, to complex animal models required for preclinical testing of new therapeutic approaches. No single model can cover the breadth of unresolved questions. This Review therefore aims to guide investigators in choosing the right model for their question. We also discuss the recent convergence of two key technologies: human stem cell and cancer stem cell culture, as well as CRISPR/Cas tools for precise genome manipulations. New functional genetic approaches in tailored models will likely fuel new discoveries, new target identification and new therapeutic strategies to tackle GBM.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available